Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Earnings Results

Key Points

• Jazz Pharmaceuticals reported a quarterly EPS of ($9.07), which missed analysts' expectations by $3.46.
• The company's stock price fell 2.5% following the earnings announcement, with shares trading at $113.20.
• Jazz Pharmaceuticals updated its FY 2025 guidance to 4.800-5.600 EPS.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64), Briefing.com reports. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the business earned $5.30 EPS. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals updated its FY 2025 guidance to 4.800-5.600 EPS.

Jazz Pharmaceuticals Price Performance

JAZZ traded down $0.78 during trading on Friday, hitting $111.30. The company's stock had a trading volume of 893,673 shares, compared to its average volume of 771,387. The company has a current ratio of 1.62, a quick ratio of 2.97 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals has a twelve month low of $95.49 and a twelve month high of $148.06. The business's fifty day simple moving average is $111.27 and its 200 day simple moving average is $117.53. The firm has a market capitalization of $6.73 billion, a price-to-earnings ratio of -16.54, a P/E/G ratio of 6.52 and a beta of 0.34.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan acquired 1,621 shares of the company's stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $103.00 per share, with a total value of $166,963.00. Following the completion of the acquisition, the director owned 101,621 shares in the company, valued at approximately $10,466,963. This trade represents a 1.62% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer directly owned 436,973 shares in the company, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock worth $47,000 after acquiring an additional 137 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter worth approximately $90,000. Focus Partners Wealth boosted its stake in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock worth $574,000 after acquiring an additional 154 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock worth $8,394,000 after acquiring an additional 33,210 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock worth $24,479,000 after acquiring an additional 7,954 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on JAZZ. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Royal Bank Of Canada decreased their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Morgan Stanley decreased their price target on Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target for the company. Finally, Piper Sandler reiterated an "overweight" rating and issued a $147.00 price target (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $181.43.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.